Key PointsGene-editing is making headlines with the FDA approval of Casgevy, the first gene-editing treatment utilizing ex-vivo CRISPR/Cas9 for sickle cell disease (SCD), granted to Vertex Pharmaceuticals and CRISPR Therapeutics.Editas is focused on in-vivo treatment for SCD utilizing their EDIT-301 technology, which uses the proprietary enzyme CRISPR/Cas12 but also collects licensing fees for Cas9 from Vertex.Intellia’s co-founder, Jennifer Doudna, won the 2020 Nobel Prize for pioneering work in CRISPR tec ...

It may seem like $100 isn't a lot of money to invest in the stock market. But over time, you can add to that total and grow your stake in a business. Investing even a small amount is a good way to at least get your feet wet and slowly gain some exposure to a stock without going all-in right away.There are plenty of good growth stocks out there where $100 will allow you to own at least one full share of the business. Three stocks investors should consider investing in for the long term are PayPal (PYPL -2.65 ...

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (CRSP -2.64%) and its collaboration partner Vertex Pharmaceuticals.But CRISPR isn't the only biotech pursuing advanced medicines, and investors are already looking for the next players that might make big breakthroughs. It's riskier to invest earlier along in a company's development, but that's precisely where the largest returns lie, which means that now is the time to ...

Key PointsVertex Pharmaceuticals received FDA approval for Casgevy for the treatment of sickle cell disease (SCD) utilizing CRISPR/Cas9 gene-editing technology.CRISPR Therapeutics partnered with Vertex in the development of Casgevy and aims to use the technology to treat more hereditary diseases.CRSP shares fell 20% following the FDA announcement and downgrade by Cowen to Underperform with a $30 price target.5 stocks we like better than CRISPR TherapeuticsOn Dec. 8, 2023, Vertex Pharmaceuticals Inc. NASDAQ: ...

If you're looking for a stock that has the potential to grow your investment to $1 million, a good move may be to invest in a strong business that's in a fast-growing industry. Gene therapy is an example of just that. The market for gene therapy is worth a relatively modest $8.7 billion this year, according to estimates from Grand View Research. But those analysts also believe that by 2030, it could soar to more than $29.5 billion, if it expands at a compounded annual growth rate of 19.5%.Gene therapies hav ...

December has been a big month for CRISPR Therapeutics (CRSP -9.01%). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment for sickle cell disease. It was a monumental decision as it also marked the first approval for a therapy utilizing the CRISPR/Cas9 gene-editing technology.Despite this positive news, shares of CRISPR Therapeutics have stalled in December. In fact, the stock is down since the news of the approval, and month to date i ...

"The thrill of victory and the agony of defeat."That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR Therapeutics (CRSP -9.01%) and Pfizer (PFE -1.88%) in 2023. CRISPR Therapeutics has enjoyed the thrill of victory, while Pfizer has experienced the agony of defeat.But which of these two biopharmaceutical stocks is the better pick for a new bull market? Motley Fool contributors Adria Cimino and Keith Speights make the argum ...

Not applicable. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. On September 7, 2023, Dr. Phuong Khanh Morrow, our Chief Medical Officer, adopted a trading arrangement intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) (a "Rule 10b5-1 trading arrangement") with respect to the sale of up to an aggregate of 94,699 common shares of the Company pursuant to the terms of such trading plan, inclusive of common shares that will be mandated to ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Citi's 18th Annual BioPharma Conference Call September 6, 2023 11:20 AM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Yigal Nochomovitz - Citigroup Yigal Nochomovitz We can get started. I'm Yigal Nochomovitz, I'm one of the biotech analysts at Citi. Next session is with the CEO of CRISPR, Sam Kulkarni. I cover CRISPR, I think, since the very beginning, since the IPO. So Sam, welcome. Thanks for doing this. Appreciate it. Sam Kulkarni Thanks fo ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 For the transition period from to . Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Accelerated filer☐ ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standard ...